1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2015-2020)

The Global Cancer Monoclonal Antibodies Market was valued at USD 27 billion for the year 2015, and is expected to grow at a CAGR of around 8-15% from 2015 to 2020. Cancer is a severe disease, which starts from a single cell; cancer genetically transforms a normal cell into a tumor cell. Gradually, it spreads to more cells. There is no one definite cause for cancer. The interaction between a person’s genetic factor and other external agents (physical carcinogens, such as ultraviolet and ionizing radiation, chemical carcinogens, and biological carcinogens) can roughly be cited as the major cause. In 2012, WHO reported 14 million new cancer cases and 8.2 million deaths due to cancer. The most common types of cancer that caused death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and esophageal cancer. There is a steady rise and incidence of cancer annually. Drugs haven’t been able to provide complete cure for any cancer. Moreover, all these drugs available for cancer as chemotherapeutic agents have adverse side-effects because the drugs tend to affect the normal, healthy cells along with the cancerous cells. Hence, there is huge amount of research and development going on all over the world to combat this deadly disease.

Monoclonal antibodies are specifically cloned antibodies that have the capability to identify cancer cells, bind to proteins on their surface and simulate an immune response. Due to their specificity, they are expected and have been proved to lessen the adverse effects of cancer to a much higher level. Most major pharmaceutical companies are investing for research on monoclonal antibodies. The drug research companies have also collaborated with many academics and institutions like National Institutes of Health, USA, National Cancer Institute, USA and many others for research and development of cancer drugs/ monoclonal antibodies. Due to the highly customizable nature of monoclonal antibodies, various organizations, research institutes and companies are using it as a tool to target various cancers.

The global monoclonal antibody market has been segmented based on:

Therapeutic application
Hodgkins and non-hodgkins lymphoma
Types of monoclonal antibodies
Murine antibodies
Chimeric and humanized antibodies
Fully humanized antibodies
Conjugated cancer therapies using monoclonal antibodies
Avastin, Rituxan, Bexxar, Kadcyla, Erbitux, Arzerra, Yervoy, Adcetris, Herceptin are some of the well-marketed monoclonal antibodies. A large patient population, severity of the disease, unavailability of good drugs and side effects of the existing drugs are the main reasons for the big void in the monoclonal antibodies market for new entrants to fill in. With only few monoclonal antibodies in the market exclusively for cancer therapies, there is always a good prospect for a new entrant. Conjugated therapies, using monoclonal antibodies, have been observed to give better results compared to stand alone treatment. Currently, there is a trend towards more research in conjugated therapies. With growing collaborations with institutes and companies, a very good market is expected in the near future. North America has the largest market for cancer monoclonal antibodies. India, China and Australia are expected to have a large market in the near future.

The key players in this market are Amgen, Bristol Meyer Squibb, GlaxoSmithKline, Roche, Eli Lilly, ImmunoGen, Novartis, Genmab and others.


Large global patient pool
Severity of the disease
Unavailability of completely curing drugs
Side effects of the existing drugs
More specificity of monoclonal antibodies in targeting cancer cells


Stringent regulatory guidelines
Long duration of research and development
Long duration of clinical trials
High cost for research and development

Table Of Contents

Global Cancer Monoclonal Antibodies Market - Growth, trend, and forecast (2015-2020)
1. Introduction

1.1 Study deliverables

1.2 Market Definition

1.3 Sizing Units

1.4 Base Currency

1.5 Review and Forecast period years

1.6 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Econometric Forecast Model

2.4 Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

5.1 Current Market Senario

5.2 Cancer Monoclonal antibody Applications

5.3 Technology Overview

5.4 New Developments

5.5 Industry Value chain analysis

5.6 product Life cycle analysis

5.7 Product Benchmarking

5.8 Investment Analysis

5.9 Porter's Five Forces

5.9.1 Bargaining Power of Suppliers

5.9.2 Bargaining Power of Consumers

5.9.3 Threat to new entrants

5.9.4 Threat to substitute products and services

5.9.5 Competitive Rivalry within the industry

6. Drivers, Restraints, Opportunities, and challenges Analysis

6.1 Market Drivers

6.1.1 Large global patient population

6.1.2 Severity of the disease with chronic nature

6.1.3 Side effects of existing drugs/ therapy

6.1.4 Specificity of Monoclonal antibodies

6.2 Market Restraints

6.2.1 Stringent Regulatory guidelines

6.3 Key Challenges

6.3.1 High Research and development cost

6.3.2 Longer duration of RandD and Clinical Trials

7. Market Segmentation

7.1 By Application

7.1.1 Breast Cancer

7.1.2 Non-small cell Lung cancer

7.1.3 Neuroblastoma

7.1.4 Melanoma

7.1.5 Gastric cancer

7.1.6 leukemia

7.1.7 Hodgkin Lymphoma

7.1.8 Malignant ascites

7.1.9 Colorectal cancer

7.1.10 non-Hodgkin Lymphoma

7.1.11 Brain Tumor

7.1.12 Lymphocytic Leukemia

7.1.13 Ovarian cancer

7.1.14 Others

7.2 By types of Monoclonal Antibodies

7.2.1 Murine Antibodies

7.2.2 Chimeric and Humaized Antibodies

7.2.3 Fully Humanized antibodies

7.3 By Conjugated Cancer therapies using Monoclonal Antibodies

7.3.1 Immunoliposomes

7.3.2 Radioimmunotherapy

7.3.3 Antibody directed enzyme prodrug therapy

7.3.4 Immunotoxins

7.3.5 Immunocytokines

7.3.6 Others

8. Market segmentation by Geography - Regional Share and forecast

8.1 North America

8.1.1 Introduction

8.1.2 United States

8.1.3 Canada

8.1.4 Rest of North America

8.2 Europe

8.2.1 Introduction

8.2.2 Germany

8.2.3 United Kingdom

8.2.4 France

8.2.5 Italy

8.2.6 Spain

8.2.7 Russia

8.2.8 Rest of Europe

8.3 Asia-Pacific (APAC)

8.3.1 Introduction

8.3.2 China

8.3.3 Japan

8.3.4 India

8.3.5 Australia

8.3.6 South Korea

8.3.7 Rest of Asia Pacific

8.4 Middle-East and Africa

8.4.1 Introduction

8.4.2 UAE

8.4.3 Saudi Arabia

8.4.4 Israel

8.4.5 Rest of Middle-east and Africa

8.5 Latin America

8.5.1 Introduction

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Mexico

8.5.5 Rest of Latin America

9. Competitive Landscape

9.1 Merger and acquisition analysis

9.2 Patent Analysis

9.3 The Challenges

10. Key Vendor Analysis

10.1 Amgen Inc.

10.2 Bristol-Meyer Squibb

10.3 GlaxoSmithKline

10.4 Roche Holding

10.5 Spectrum Pharmaceuticals

10.6 Merck and Co. Inc.

10.7 Eli Lilly and co.

10.8 ImmunoGen Inc.,

10.9 Seattle Genetics

10.10 Janssen Biotech Inc.

10.11 Genmab

10.12 Novartis AG

11. Analyst outlook for Investment opportunities

12. Future Outlook of the market

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6 995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Ovarian Cancer: Analytical Tool

August 2016 $ 7 125

Download Unlimited Documents from Trusted Public Sources

Ovarian Cancer Statistics in the UK

  • October 2016
    39 pages
  • Ovarian Cancer  



  • United Kingdom  


View report >

Cancer Statistics in the US - Forecast

  • October 2016
    38 pages
  • Cancer  


  • United States  

View report >

Cancer Statistics in the US

  • October 2016
    9 pages
  • Pathology  


  • United States  

View report >


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.